Source: Annual Congress 2012 - New biomarkers for lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
S. Abdel Ghani, N. Elmelegy, A. Mohamed-Hussein, R. Hanna (Assiut, Egypt). Potential angiogenic biomarkers in patients with non small cell lung cancer: Possible implications. Eur Respir J 2012; 40: Suppl. 56, 4220

Member's Comments

No comment yet.

Related content which might interest you: Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Epithelial cell migration as a potential therapeutic target in early lung cancer Source: Eur Respir Rev 2017; 26: 160069 Year: 2017 Surgery for non small cell lung cancer (NSCLC) and functional limits: is there a possible beneficial role of preoperative pulmonary rehabilitation? Source: Eur Respir J 2004; 24: Suppl. 48, 522s Year: 2004 Assessing the relevance of biological prognostic indices in predicting survival in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Prognostic and potential therapeutic impact of prostate specific membrane antigen expression in non-small cell lung cancer Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Prognostic implications of smoking in patients with advanced lung adenocarcinoma excluding positive mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Fibrosis-specific stem-like cells in peripheral IPF lung: Characteristics and potential role Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 Validation and comparison of several published prognostic systems for patients with small cell lung cancer Source: Eur Respir J 2011; 38: 657-663 Year: 2011 Possible predictors of the bronchodilation test response within lung function assessment of patients with operable lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005 Molecular epidemiology in non small cell lung cancer (NSCLC) tumors: implication of gender and histological features Source: Eur Respir J 2006; 28: Suppl. 50, 335s Year: 2006 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Issues other than tissue: non-invasive biomarkers of early stage lung cancer Source: Virtual Congress 2020 – Will the pulmonologist still play a role in the management of screen-detected pulmonary nodules? Year: 2020 Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Diverse effects of PAI-1 proteins on lung and prostate cancer cell invasion Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Common therapeutic approaches in IPF and lung cancer Source: Research Seminar 2015 Year: 2015 Host–microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease Source: Eur Respir J, 56 (2) 1902320; 10.1183/13993003.02320-2019 Year: 2020